Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Moderna, one of the leading horses in the coronavirus vaccine race, has already made deals at between $32 and $37 a dose for some foreign countries. The U.S. price is expected to be lower. -
If the company's vaccine candidate pans out, Americans can receive it for free under the deal. The arrangement is part of the U.S. government's push to have a vaccine widely available by January. -
Companies that made hats, socks and teddy bears have started producing surgical masks to protect people from COVID-19. Some sellers exaggerate their standing with the Food and Drug Administration. -
An experimental COVID-19 medicine that has been shown to shorten the time people with severe illness have to stay in the hospital finally has a price tag that's lower than some analysts expected. -
As Operation Warp Speed pushes to develop a COVID-19 vaccine in record time, the number of candidates is being narrowed. The factors guiding the decisions about which projects to fund is unclear. -
Gilead Sciences is donating its initial supply of the experimental treatment for COVID-19. The federal government is deciding where the scarce medicine goes, and there are questions about the choices. -
Gilead Sciences has committed to donating the initial supply of the experimental antiviral drug. But executives said the company will need to make expanded production of the treatment sustainable. -
On Friday, the Food and Drug Administration authorized emergency use of remdesivir for patients with severe cases of COVID-19. Drugmaker Gilead Sciences' lobbying hit a new high in the first quarter. -
Experts say it could be dangerous to rely on overseas production of medicine in a crisis, but the U.S. largely does. Rebuilding domestic capacity would take years and substantial investments. -
COVID-19 has led to the suspension of many clinical studies of experimental treatments. About a quarter of the stopped trials involved new cancer treatments, an NPR analysis finds.
